Aberrant Mucin5B Expression in Lung Adenocarcinomas Detected by ITRAQ Labeling Quantitative Proteomics and Immunohistochemistry

Overview

Journal Clin Proteomics

Publisher Biomed Central

Date 2013 Nov 2

PMID 24176033

Citations 11

Authors

Yan Li

Xiangchun Wang

Minghui Ao

Edward Gabrielson

Frederic Askin

Hui Zhang

Qing Kay Li

Affiliations

Soon will be listed here.

Abstract

Background: Lung cancer is the number one cause of cancer-related deaths in the United States and worldwide. The complex protein changes and/or signature of protein expression in lung cancer, particularly in non-small cell lung cancer (NSCLC) has not been well defined. Although several studies have investigated the protein profile in lung cancers, the knowledge is far from complete. Among early studies, mucin5B (MUC5B) has been suggested to play an important role in the tumor progression. MUC5B is the major gel-forming mucin in the airway. In this study, we investigated the overall protein profile and MUC5B expression in lung adenocarcinomas, the most common type of NSCLCs.

Methods: Lung adenocarcinoma tissue in formalin-fixed paraffin-embedded (FFPE) blocks was collected and microdissected. Peptides from 8 tumors and 8 tumor-matched normal lung tissue were extracted and labeled with 8-channel iTRAQ reagents. The labeled peptides were identified and quantified by LC-MS/MS using an LTQ Orbitrap Velos mass spectrometer. MUC5B expression identified by iTRAQ labeling was further validated using immunohistochemistry (IHC) on tumor tissue microarray (TMA).

Results: A total of 1288 peptides from 210 proteins were identified and quantified in tumor tissues. Twenty-two proteins showed a greater than 1.5-fold differences between tumor and tumor-matched normal lung tissues. Fifteen proteins, including MUC5B, showed significant changes in tumor tissues. The aberrant expression of MUC5B was further identified in 71.1% of lung adenocarcinomas in the TMA.

Discussions: A subset of tumor-associated proteins was differentially expressed in lung adenocarcinomas. The differential expression of MUC5B in lung adenocarcinomas suggests its role as a potential biomarker in the detection of adenocarcinomas.

Citing Articles

Multiplex analysis for the identification of plasma protein biomarkers for predicting lung cancer immunotherapy response.

Hong M, Lee S, Cho B, Hong M, Lim S, Kwon N Ther Adv Med Oncol. 2024; 16:17588359241254218.

PMID: 38779033 PMC: 11110506. DOI: 10.1177/17588359241254218.

Proteomic analyses identify HK1 and ATP5A to be overexpressed in distant metastases of lung adenocarcinomas compared to matched primary tumors.

Pasternack H, Polzer M, Gemoll T, Kumpers C, Sauer T, Lazar-Karsten P Sci Rep. 2023; 13(1):20948.

PMID: 38016997 PMC: 10684588. DOI: 10.1038/s41598-023-47767-5.

Interleukin-11: A Potential Biomarker and Molecular Therapeutic Target in Non-Small Cell Lung Cancer.

Leung J, Ng B, Lim W Cells. 2022; 11(14).

PMID: 35883698 PMC: 9318853. DOI: 10.3390/cells11142257.

Identification of differentially expressed proteins in the injured lung from zinc chloride smoke inhalation based on proteomics analysis.

Xie X, Zhao J, Xie L, Wang H, Xiao Y, She Y Respir Res. 2019; 20(1):36.

PMID: 30770755 PMC: 6377712. DOI: 10.1186/s12931-019-0995-0.

Quantitative proteomic analysis of mitochondrial proteins differentially expressed between small cell lung cancer cells and normal human bronchial epithelial cells.

Li W, Zhang W, Deng W, Zhong Y, Zhang Y, Peng Z Thorac Cancer. 2018; 9(11):1366-1375.

PMID: 30198174 PMC: 6209793. DOI: 10.1111/1759-7714.12839.

References

Aberle D, Adams A, Berg C, Black W, Clapp J, Fagerstrom R . Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5):395-409. PMC: 4356534. DOI: 10.1056/NEJMoa1102873. View

Konicek B, Stephens J, McNulty A, Robichaud N, Peery R, Dumstorf C . Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases. Cancer Res. 2011; 71(5):1849-57. DOI: 10.1158/0008-5472.CAN-10-3298. View

Copin M, Buisine M, Leteurtre E, Marquette C, Porte H, Aubert J . Mucinous bronchioloalveolar carcinomas display a specific pattern of mucin gene expression among primary lung adenocarcinomas. Hum Pathol. 2001; 32(3):274-81. DOI: 10.1053/hupa.2001.22752. View

Tian T, Hao J, Xu A, Hao J, Luo C, Liu C . Determination of metastasis-associated proteins in non-small cell lung cancer by comparative proteomic analysis. Cancer Sci. 2007; 98(8):1265-74. PMC: 11158557. DOI: 10.1111/j.1349-7006.2007.00514.x. View

Hollingsworth M, Swanson B . Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer. 2003; 4(1):45-60. DOI: 10.1038/nrc1251. View

Chen G, Gharib T, Huang C, Thomas D, Shedden K, Taylor J . Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res. 2002; 8(7):2298-305. View

Beroukhim R, Mermel C, Porter D, Wei G, Raychaudhuri S, Donovan J . The landscape of somatic copy-number alteration across human cancers. Nature. 2010; 463(7283):899-905. PMC: 2826709. DOI: 10.1038/nature08822. View

Perrais M, Pigny P, Copin M, Aubert J, Van Seuningen I . Induction of MUC2 and MUC5AC mucins by factors of the epidermal growth factor (EGF) family is mediated by EGF receptor/Ras/Raf/extracellular signal-regulated kinase cascade and Sp1. J Biol Chem. 2002; 277(35):32258-67. DOI: 10.1074/jbc.M204862200. View

Poletti V, Poletti G, Murer B, Saragoni L, Chilosi M . Bronchoalveolar lavage in malignancy. Semin Respir Crit Care Med. 2007; 28(5):534-45. DOI: 10.1055/s-2007-991526. View

10.

Nambu Y, Beer D . Altered surface markers in lung cancer. Lack of cell-surface Fas/APO-1 expression in pulmonary adenocarcinoma may allow escape from immune surveillance. Methods Mol Med. 2002; 74:259-66. DOI: 10.1385/1-59259-323-2:259. View

11.

Xu N, Wang Y, Pan W, Xiao B, Wen Y, Chen X . Human alpha-defensin-1 inhibits growth of human lung adenocarcinoma xenograft in nude mice. Mol Cancer Ther. 2008; 7(6):1588-97. DOI: 10.1158/1535-7163.MCT-08-0010. View

12.

Dekker J, Rossen J, Buller H, Einerhand A . The MUC family: an obituary. Trends Biochem Sci. 2002; 27(3):126-31. DOI: 10.1016/s0968-0004(01)02052-7. View

13.

Oh J, Krapfenbauer K, Fountoulakis M, Frischer T, Lubec G . Evidence for the existence of hypothetical proteins in human bronchial epithelial, fibroblast, amnion, lymphocyte, mesothelial and kidney cell lines. Amino Acids. 2004; 26(1):9-18. DOI: 10.1007/s00726-003-0060-6. View

14.

MacDermed D, Khodarev N, Pitroda S, Edwards D, Pelizzari C, Huang L . MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients. BMC Med Genomics. 2010; 3:16. PMC: 2876055. DOI: 10.1186/1755-8794-3-16. View

15.

Nakamori S, Ota D, Cleary K, SHIROTANI K, Irimura T . MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. Gastroenterology. 1994; 106(2):353-61. DOI: 10.1016/0016-5085(94)90592-4. View

16.

Zhang H, Li X, Martin D, Aebersold R . Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol. 2003; 21(6):660-6. DOI: 10.1038/nbt827. View

17.

Bortner Jr J, Das A, Umstead T, Freeman W, Somiari R, Aliaga C . Down-regulation of 14-3-3 isoforms and annexin A5 proteins in lung adenocarcinoma induced by the tobacco-specific nitrosamine NNK in the A/J mouse revealed by proteomic analysis. J Proteome Res. 2009; 8(8):4050-61. PMC: 2761226. DOI: 10.1021/pr900406g. View

18.

Komatsu M, Jepson S, Arango M, Carothers Carraway C, Carraway K . Muc4/sialomucin complex, an intramembrane modulator of ErbB2/HER2/Neu, potentiates primary tumor growth and suppresses apoptosis in a xenotransplanted tumor. Oncogene. 2001; 20(4):461-70. DOI: 10.1038/sj.onc.1204106. View

19.

Chen H, Suzuki M, Nakamura Y, Ohira M, Ando S, Iida T . Aberrant methylation of FBN2 in human non-small cell lung cancer. Lung Cancer. 2005; 50(1):43-9. DOI: 10.1016/j.lungcan.2005.04.013. View

20.

Tian Y, Tan A, Sun X, Olson M, Xie Z, Jinawath N . Quantitative proteomic analysis of ovarian cancer cells identified mitochondrial proteins associated with Paclitaxel resistance. Proteomics Clin Appl. 2010; 3(11):1288-95. PMC: 2989613. DOI: 10.1002/prca.200900005. View